KNSA vs RXRX: which is the better buy in 2026?
On Alexandria's Compass, Kiniksa Pharmaceuticals International, plc has the edge with a 85/100 score versus 82/100 for RXRX. Here is how they stack up, factor by factor.
Kiniksa Pharmaceuticals International, plc
NASDAQ:KNSA
A one-drug company quietly becoming a two-drug franchise, with the second drug potentially bigger than the first.
Full KNSA analysisRecursion Pharmaceuticals
NASDAQ:RXRX
Recursion's AI drug discovery platform is real science, but $208M annual cash burn against a $1.9B market cap demands clinical proof soon.
Full RXRX analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is KNSA or RXRX the better buy in 2026?
By Compass Score, Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) edges it at 85/100 versus 82/100 for RXRX. Both scores update weekly and reflect a contrarian, forward-looking read, not a recommendation.
How does Alexandria compare KNSA and RXRX?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.